MANUAL CATHETER ASSOCIATED BLOOD STREAM INFECTION (CABSI) SURVEILLANCE

Slides:



Advertisements
Similar presentations
Risk Stratification in Renal Care Mary Jane McKendry Vice President, Operations Fresenius Disease Management Optimal Renal Care.
Advertisements

Surveillance of nosocomial infections Johnny, Courtesy, Brocolli.
Network 11 Quality Update Chris Singer, MAN, RN, CNN December 4, 2008.
Principal Investigator: Mr Evan Alexandrou Clinical Nurse Specialist Central Venous Access & Intensive Care, Liverpool Hospital, Australia Lecturer School.
Spotlight Case October 2010 Dangerous Dialysis. 2 Source and Credits This presentation is based on the October 2010 AHRQ WebM&M Spotlight Case –See the.
Hemodialysis Adequacy
Renal Replacement Therapy: What the PCP Needs to Know.
Infection Control in CKD A Culture of Safety Leona Dinnan, RN, CDN.
Intermountain ESRD – Network 15 Karen Strott, RN Linda Pleiman, RN !
Strategies for Improving Adequacy Decreasing the Risk of Premature Death Educate Your Dialysis Team Review Proper Procedure for Drawing Lab Samples - Lab.
Chapter 3: Clinical Indicators and Preventive Care 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Chapter 2: Healthy People A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
A Brief Introduction to Epidemiology - VII (Epidemiologic Research Designs: Demographic, Mortality & Morbidity Studies) Betty C. Jung, RN, MPH, CHES.
Assessing Disease Frequency
Dialysis Facility Compare Valarie Ashby Co-Managing Director UM-KECC.
Hallauer 06/20011 Outcome evaluation of an universal hepatitis B immunisation programme Johannes F. Hallauer M.D. Health Systems Research Charité, Humboldt.
Hospital Surveillance. Impact of infectious diseases  IDs are considered to be the leading cause of death  Mass population movement  Emerging and re-emerging.
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Azara Proprietary & Confidential Controlling High Blood Pressure 2014 Measure Changes Improving Patient Outcomes through Data.
~ Make a Difference ~ Become a Nephrology Nurse. Incidence (rate of occurrence) –220 per million in 1992 –334 per million in 2000 Prevalence (number of.
………………..…………………………………………………………………………………………………………………………………….. Quality Improvement in Health Care Nationwide Children’s Sheilah Harrison September 2011.
NOSOCOMIAL INFECTION SURVEILLANCE METHODS Masud Yunesian, M.D., Epidemiologist.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Infections in the dialysis population: A major communicable disease issue! Allan J. Collins, MD, FACP Professor of Medicine University of Minnesota Director,
Single Unit Transfusion Guideline for Red Blood Cell Transfusion
Revised for 2013 Shannon Hein RN, CPN(C).  published in the Canadian Medical Association Journal in May 2004  Found an overall incidence rate of adverse.
SM Gatmiri, MD, Nephrologist Imam Khomeini Hospital,
1 Terri Conner,PhD Nybeck Analytics Partnership for Patients 14 th May 2012 USE OF MEDICARE DIAGNOSIS AND PROCEDURE CODES TO IMPROVE DETECTION OF SURGICAL.
Bundling…..Will we survive? Thomas E. Amitrano BSN, MPA, RN.
Vascular access The KidneyCare Audit. The challenge of vascular access – Renal National Service Framework Standard 3 “All children, young people and adults.
Hemodialysis. Hemodialysis (also haemodialysis) is a method for removing waste products such as potassium and urea, as well as free water from the blood.
Hemodialysis Catheter Infection Reduction Kathleen Maloney, RN State University of New York Institute of Technology Department of Nursing Introduction.
1 PREPARATION AND RESPONSE OF THE HEALTH SERVICES TO AN INFLUENZA PANDEMIC.
CHRONIC KIDNEY DISEASE National Healthcare Quality and Disparities Report Chartbook on Effective Treatment.
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, AN NCI COMPREHENSIVE CANCER CENTER – Tampa, FL MOFFITT ( ) © 2010.
HEALTH CARE ASSOCIATED INFECTION دکترافشین محمد علیزاده متخصص عفونی عضوهیئت علمی دانشگاه علوم پزشکی شهیدبهشتی بیمارستان آیت ا...طالقانی.
Haemodialysis Vascular Access: Recent Trends From ANZDATA Dr Kevan Polkinghorne Monash Medical Centre ANZSN September 2007.
Al wakeel J, Bayoumi M, Al Ghonaim M, Al Harbi A, Al Swaida A, Mashraqy A.
Review of literature and report of experience with erythropoietin in ESRD populations Summary to FDA Cardio Renal Committee J. Michael Lazarus, M.D. CMO.
Hemodialysis access: guidelines, evidence and controversies Marc R Lilien, MD, PhD Pediatric nephrologist.
Impact of Renal Transplantation on Psychosocial Status of HIV Positive Patients DR. Prof. D. K. AGARWAL MD,DM,DNB,MAMS,FICP,FISN Senior Consultant Nephrologist,
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 8: Pediatric ESRD.
AHRQ Safety Program for Long-term Care: HAIs/CAUTI Infection Prevention: Surveillance Essentials in Preventing Health Care-Associated Infections How to.
Hospital Based Surveillance to Estimate the Burden of Rotavirus Gastroenteritis Among European Children Younger than 5 Years of Age Johannes Foster, Alfredo.
Dialysis Clinic Process Improvement Analysis Adam Roy Dorothy Fisher Janelle Bryant Joel Mikuta Sherri Mesquita Michelle Himes.
REDUCING CATHETER ASSOCIATED URINARY TRACT INFECTIONS CLINICAL EXCELLENCE COMMISSION 2015 URINE COLLECTION, CULTURE and CATHETERISATION IN ACUTE SETTINGS.
Outlines At the completion of this lecture the student will be able to identify the concept and related terms of: Infection- Infection control-
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 2: Healthy People 2020.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 4: Vascular Access.
Catheter-Related Blood Stream Infections A Phase 2 Randomized, Controlled Trial of Dalbavancin vs. Vancomycin Tim Henkel, MD, PhD Executive VP and Chief.
Screening – a discussion in clinical preventive medicine Galit M Sacajiu MD MPH.
以多重死因資料比較台灣美國腦中風 併發吸入性肺炎之趨勢 奇美醫學中心 張嘉祐醫師. Stroke Statistics -- A Report From the American Heart Association Approximately 56% of stroke deaths in 2009.
Dr Michelle Webb Renal Consultant, Associate Medical Director Patient Safety, East Kent Hospitals University NHS Foundation Trust and Co-lead for Sepsis.
Yousef I. Aljeesh, PhD, RN Said Abusalem, PhD, RN Naeem Alkariri, MSN, RN John A. Myers, PhD, MSPH Fawwaz Alaloul, PhD, RN Staff Developed IP Program Increases.
Epidemiological measureas. How do we determine disease frequency for a population?
The STARRT Trial Source: Piwko C, Vicente C, Marra L, et al. The STARRT trial: a cost comparison of optimal vs sub-optimal initiation of dialysis in Canada.
USRDS USRDS 2002 adr Incident counts by initial modality figure 7.1 patients age 19 years & younger.
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Figure 10.1 Dialysis unit counts, by unit affiliation, 2011–2014
2017 Annual Data Report Healthy People 2020.
2016 Annual Data Report, Vol 2, ESRD, Ch 4
Results of the STRUTI project
Infrared Therapy Treatment for Arterio Venous Fistula
CHAPTER 5 Paediatric Renal Replacement Therapy
2018 Annual Data Report Volume 3: Healthy People 2020
Recognising sepsis and taking action
Lorna Perez, Ethan Gough
Maryland HCW Influenza Vaccination Survey Highlights
CIC Practice Questions
Presentation transcript:

MANUAL CATHETER ASSOCIATED BLOOD STREAM INFECTION (CABSI) SURVEILLANCE November 2012 Infection Control Unit Quality in Medical Care Section Medical Development Division Ministry of Health

INTRODUCTION Regardless of the numerous reports on the adverse impact associated with the use of catheters as a vascular access for haemodialysis (HD), Central Venous Catheters (CVCs) remains as an important tool in the delivery of adequate dialysis. In incident HD patients, CVCs provide an instant access to the circulation. In chronic or prevalent HD patients, CVCs are useful as a bridging gap for patients who have problems with poor maturation of their native fistula and while awaiting fistula maturation.

INTRODUCTION - Cont The use of CVCs is associated with a high morbidity, mortality and increased health care costs due to infectious complications. The risk of infection in CVCs is 5-10 fold higher than dialyzing with a native fistula or graft(1). Vascular access related infection and other complications frequently result in prolonged hospitalization and account for more than one third of the cost of ESRD management. The reported mortality rate ranges between 12 to 25.9%

INTRODUCTION - Cont Despite numerous attempts to encourage the use of fistula, the usage of CVCs in the USA remains high with nearly 65% of patients using CVCs at the first outpatient HD treatment (1) The 19th Report of Malaysian Dialysis and Transplant Registry showed that the prevalence rate of End Stage Renal Disease has increased from 368 per million population in 2002 to 900 per million population in 2011. The usage of CVC in prevalent or chronic HD patients has also increased from 3% to 8.1% during the same period. This is an underestimation as the predominant usage of CVCs for HD is in the incident patients.

INTRODUCTION - Cont The growing numbers of patients who require haemodialysis combined with the increasing number of patients who are unable to use native vascular access other than a CVC stress the need to monitor the rate of CABSI and the importance of strategies to prevent it.

OBJECTIVES General to assess the rate of CABSI in CVC for HD in MOH hospitals with the aim to reduce morbidity and mortality related to CABSI

OBJECTIVES - Cont Specific: To determine the incidence rate of CABSI in CVC for HD in selected MOH hospitals to identify risk factors that predispose patient to CABSI in CVC for HD to compare the rate of CABSI among the selected hospitals to determine the average catheter days before infection to determine rate of CVC removal due to infection

METHODOLOGY Population under surveillance All patients who has a CVC for HD inserted and receiving haemodialysis or extracorporeal therapy in Ministry of Health facilities. 

Case Definition All patients who are currently receiving haemodialysis receiving haemodialysis or extracorporeal therapy via CVC in Ministry of Health facilities with CABSI. CABSI is defined as: clinical signs and symptoms of infection (fever, chills and/or hypotension) AND a positive peripheral blood culture AND no other apparent source of infection.

Exclusion Criteria Patient defaulted treatment more than 72hours from the last haemodialysis treatment Patient from private haemodialysis facility with evidence of current infection during presentation CVC inserted outside MOH facilities

End of Catheter Days The end of catheter days can be determined through one of the following: Date of discharge (Discharge date from HD facilities plus 72hours; to allow cases that developed CABSI within the specified period) Date of Catheter removal Date of Death

DATA COLLECTION All patients who have a CVC inserted for HD will be identified by a designated personnel . Upon insertion of CVC for HD , CABSI Coordinator (Staff Nurse or Medical Assistant) should fill up : Surveillance Form For Catheter Associated Blood Stream Infection In Ministry Of Health Haemodialysis Facility CABSI/MOH/2012/1 (Appendix I )

DATA COLLECTION - Cont fill up item A, B, C (1 to 4) - Upon CVC insertion fill up item C (5 to 6) - Upon removal of catheter or discharge (discharge from haemodialysis facility or died) If patient developed infection, proceed to item D and fill up Surveillance Form For Catheter Associated Blood Stream Infection In Ministry Of Health Haemodialysis Facility CABSI/MOH/2012/2 as in Appendix II

DATA COLLECTION - Cont Data to be collected and analyzed by the CABSI Coordinator on monthly basis. CABSI Database (Appendix III to VIII) provided by the MOH will be used as a tool in analysis. It will generate results automatically. Upon completion, CABSI Coordinator has to fill up Reporting Form of Catheter Associated Blood Stream Infection in MOH Haemodialysis Facility CABSI/MOH/2012/3 as in Appendix IX according to the results generated from the CABSI Database.

DATA COLLECTION - Cont Completed CABSI/MOH/2012/3 form to be verified by the respective Hospital Nephrologists. CABSI/MOH/2012/1 and CABSI/MOH/2012/2 forms to be kept at respective hospital. A completed and verified CABSI/MOH/2012/3 form to be submitted to the National Secretariat by 10th of every 2 subsequent month. Further reporting and analysis will be performed by the National Secretariat.

DATA ANALYSIS AND REPORTING The Catheter Days will be used as denominators to calculate the incidence rate of CRBSI in each hospital. Following data will be collected: Monthly catheter days Cumulative catheter days 

CABSI RATE Monthly CABSI Rate = No. of CABSI for X Month x 1000 Total Catheter Days for X Month Cumulative CABSI Rate =Total No. of CABSI for Cumulative Month x 1000 Total Catheter Days for Cumulative Month

Rate for CVC Removal Due to Infection = No. of CVC Removed Due To CABSI x 100 No. of Patient with CVC a) Monthly b) Cumulatively

DATA ANALYSIS AND REPORTING - Cont All hospitals should send the aggregated data (Reporting Form of Catheter Associated Blood Stream Infection in MOH Haemodialysis Facility CABSI/MOH/2012/3 ) on monthly basis to the National Secretariat. The data will be analyzed and result will be disseminated every 6-monthly. A yearly report will be published and disseminated to all the states.

PROCESS FLOW CHART FOR CABSI SURVEILLANCE MANAGEMENT APPENDIX VIII Patient in the facility with newly inserted catheter [NEW CASE] Patient receiving haemodialysis or extracorporeal therapy in MOH facility with existing catheter [OLD CASE] Fill up CABSI/MOH/2012/1 form (Appendix I) Calculate the monthly and cumulative denominator (catheter days) at the end of the month Development of Infection NO Fill up CABSI/MOH/2012/2 form (Appendix II) YES Data compilation

Fill up CABSI/MOH/2012/3 form (Appendix IX) Completed CABSI/MOH/2012/3 form (Appendix III) to be verified by Nephrologist Verified CABSI/MOH/2012/3 form to be sent to Infection Control Unit, MOH Data management

REFERENCE United States Renal Data System 2011 Annual Data Report: Chapter 2. Clinical Indicators and Preventive Care. USRDS website: www.usrds.org Burr R et al. The cost of vascular access infections: three years experience from a single outpatient dialysis center. Hemodialysis International 2003;7: 73 -104 Liu JW et al. Nosocomial blood-stream infections in patients with ESRD; excess length of stay, extra cost and attributed mortality. Hosp Infect 2002; 50: 224-7 19th Report Of The Malaysian Dialysis & Transplant Registry 2011. Ed Lim YN, Ong LM, Goh BL. Available on the MSN website: http://www.msn.org.my.nrr Deborah Tomlinson et all. Defining Bloodstream Infections Related to Central Venous Catheters in Patients With Cancer: A Systematic Review. Available on http://cid.oxfordjournals.org/  An APIC Guide 2000 . Guide to the Elimination of Catheter-Related Bloodstream Infections

THANK YOU